JP2008007412A - Involucrin production promoter and epidermal keratinization-normalizing agent - Google Patents

Involucrin production promoter and epidermal keratinization-normalizing agent Download PDF

Info

Publication number
JP2008007412A
JP2008007412A JP2006176086A JP2006176086A JP2008007412A JP 2008007412 A JP2008007412 A JP 2008007412A JP 2006176086 A JP2006176086 A JP 2006176086A JP 2006176086 A JP2006176086 A JP 2006176086A JP 2008007412 A JP2008007412 A JP 2008007412A
Authority
JP
Japan
Prior art keywords
involucrin
extract
skin
involucrin production
fruit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006176086A
Other languages
Japanese (ja)
Inventor
Akinori Kiso
昭典 木曽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maruzen Pharmaceutical Co Ltd
Original Assignee
Maruzen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maruzen Pharmaceutical Co Ltd filed Critical Maruzen Pharmaceutical Co Ltd
Priority to JP2006176086A priority Critical patent/JP2008007412A/en
Publication of JP2008007412A publication Critical patent/JP2008007412A/en
Pending legal-status Critical Current

Links

Abstract

<P>PROBLEM TO BE SOLVED: To provide an involucrin production promoter and an epidermal keratinization-normalizing agent by finding an ingredient having production promoting action of involucrin which is a CE (cornified envelope) precursor protein in epidermis from natural products and including the ingredient as an active ingredient. <P>SOLUTION: The present invention utilizes that one or more kinds of extracts of plants selected from yeast, Prunus persica B., Aloe ferox;africana Miller, Rosa multiflora Thunberg, Calendula officinalis L., Arnica montana L., Citrus aurantium L., Lavandula vera D.C., Hypericum erectum Thunb., or Hypericum perforatum L., Citrus unshiu Markovich, Melissa officinalis L., Luffa cylindrica M. Roemen and Equisetum arvense L. have involucrin production promoting action and karatinization-normalizing action. <P>COPYRIGHT: (C)2008,JPO&INPIT

Description

本発明は、植物からの抽出物を有効成分とするインボルクリン産生促進剤及び表皮角化
正常化剤に関する。
The present invention relates to an involucrin production promoter and an epidermal keratinization normalizing agent comprising an extract from a plant as an active ingredient.

皮膚は、外界からの刺激、例えば、乾燥、紫外線、その他の物理的、化学的刺激を緩和したり、水分等の体内成分の喪失を防御したりする機能を有している。この重要な機能は、皮膚のバリア機能と呼ばれ、その機能維持に重要な役割を担っているのが角層である。   The skin has a function of alleviating external stimuli such as dryness, ultraviolet rays, and other physical and chemical stimuli and protecting the loss of body components such as moisture. This important function is called a skin barrier function, and the stratum corneum plays an important role in maintaining the function.

角層は、表皮角化細胞が終末分化して形成された角質細胞と、細胞間を埋める細胞間脂質から形成される。セラミドを主成分とする細胞間脂質は、ラメラ構造を形成することにより、角層バリア機能を担っている。一方、角質細胞は、ケラチン線維を主成分とし、膜の裏打ち蛋白であるコーニファイドエンベロープ(角質肥厚膜、以下「CE」と略)という疎水的で強靭な細胞膜様構造物に覆われている。CEは、表皮角化細胞の分化に従って細胞内で産生されるインボルクリン、ロリクリンなど複数のCE前駆体蛋白質が、酵素トランスグルタミナーゼにより架橋され不溶化して形成され、このCEが皮膚のバリア機能に密接に関与している。さらに、その一部にはセラミド等が共有結合し、疎水的な構造をとることで細胞間脂質のラメラ構造の土台を供給し、角層バリア機能及び皮膚の水分保持機能の基礎が形成される。   The stratum corneum is formed from keratinocytes formed by terminal differentiation of epidermal keratinocytes and intercellular lipids that fill the space between the cells. Intercellular lipids mainly composed of ceramide have a stratum corneum barrier function by forming a lamellar structure. On the other hand, keratinocytes are mainly composed of keratin fibers and covered with a hydrophobic and strong cell membrane-like structure called a cornified envelope (keratin thickened membrane, hereinafter abbreviated as “CE”) which is a membrane lining protein. CE is formed by cross-linking and insolubilizing a plurality of CE precursor proteins such as involucrin and loricrin produced in the cells according to the differentiation of epidermal keratinocytes, and this CE is closely related to the barrier function of the skin. Is involved. Furthermore, ceramide and the like are covalently bonded to a part of them, and the base of the lamellar structure of intercellular lipids is supplied by taking a hydrophobic structure, thereby forming the basis of the stratum corneum barrier function and the skin water retention function .

角質細胞は、表皮角化細胞の分化(角化)によって次々と新しく作られ、古くなった角質細胞は垢として角層から脱落していく。これが、皮膚のターンオーバーと言われる現象である。ターンオーバーのサイクルは、正常な皮膚では約4週間と言われているが、加齢、乾燥、紫外線などの影響によりターンオーバー速度に異常が生じると、ラメラ構造の乱れやCEが不完全な状態で形成された、いわゆる不全角化が誘発され、角質細胞や細胞間脂質の構造に異常が生じ角層の水分保持機能およびバリア機能は低下する。このことが肌荒れ、乾燥肌等の皮膚の老化症状につながると考えられる。また、乾癬やアトピー性皮膚炎の患者では、バリア機能が低下した皮疹部で未熟なCEが高頻度に観察され、CEが正しく形成されることが皮膚のバリア機能に非常に重要であると考えられている(非特許文献1)。   The keratinocytes are newly created one after another by the differentiation (keratinization) of the epidermal keratinocytes, and the old keratinocytes fall off from the stratum corneum as plaque. This is a phenomenon called skin turnover. It is said that the turnover cycle is about 4 weeks for normal skin, but if the turnover speed becomes abnormal due to the effects of aging, drying, ultraviolet rays, etc., the lamella structure is disturbed and CE is incomplete. In other words, the so-called aberrant keratinization is induced, the structure of corneocytes and intercellular lipids is abnormal, and the water retention function and barrier function of the stratum corneum are reduced. This is thought to lead to skin aging symptoms such as rough skin and dry skin. In patients with psoriasis and atopic dermatitis, immature CE is frequently observed in the skin area where the barrier function is reduced, and the correct formation of CE is very important for the barrier function of the skin. (Non-Patent Document 1).

即ち、表皮においてトランスグルタミナーゼやインボルクリンの産生を促進することにより角質細胞の角化を促進し、健全な角層の形成を促すことによって、皮膚のバリア機能および水分保持機能を高め、乾燥肌、荒れ肌、アトピー性皮膚炎、乾癬などの皮膚症状を予防又は改善することができると考えられる。このような考えに基づき、インボルクリン産生促進作用を有するものとして、セイロンテツボクの種子抽出物(特許文献1)、キリンサイ抽出物(非特許文献2)等が知られている。
特開2005−213187公報 Experimental Dermatology 12:591−601(2003) 日本香粧品科学会誌Vol.27:6−10(2003)
That is, by promoting the production of transglutaminase and involucrin in the epidermis, keratinization of keratinocytes is promoted, and the formation of a healthy stratum corneum is promoted, so that the skin barrier function and water retention function are enhanced, dry skin, rough skin It is considered that skin symptoms such as atopic dermatitis and psoriasis can be prevented or ameliorated. Based on this idea, Ceylon tetsuboku seed extract (Patent Document 1), Kirinsai extract (Non-Patent Document 2) and the like are known as having an involucrin production promoting action.
JP-A-2005-213187 Experimental Dermatology 12: 591-601 (2003) Japanese Cosmetic Science Society Vol. 27: 6-10 (2003)

しかしながら、これまで角層バリア機能の低下に用いられていた成分は、細胞間脂質の成分を補うことや、皮膚に被膜を形成させることにより皮膚バリア機能の改善効果を発揮していたが、角質細胞のCEの構造については改善効果が十分でない場合もあり、健全なCEの形成に働きかける成分の開発が望まれていた。   However, the components that have been used to lower the stratum corneum barrier function so far have been effective in improving the skin barrier function by supplementing the components of intercellular lipids and forming a film on the skin. The improvement of the CE structure of the cells may not be sufficient, and it has been desired to develop a component that works to form a healthy CE.

そこで本発明においては、天然物の中から、表皮においてCE前駆体蛋白質であるインボルクリンの産生促進作用を有する成分を見出し、これらを有効成分として含有するインボルクリン産生促進剤並びに表皮角化正常化剤を提供することを目的とした。   Therefore, in the present invention, an ingredient having an action of promoting the production of involucrin which is a CE precursor protein in the epidermis is found from natural products, and an involucrin production promoter and an epidermal keratinizing normalizing agent containing these as active ingredients are found. The purpose was to provide.

前記課題を解決するために、種々検討を行ったところ、酵母、モモ、アロエ、ノイバラ、トウキンセンカ、アルニカ、ダイダイ、ラベンダー、オトギリソウ、ウンシュウミカン、メリッサ、ヘチマ及びスギナから選ばれる1種又は2種以上の抽出物にインボルクリン産生促進作用を見出し、本発明を完成するに至った。   In order to solve the above-mentioned problems, various studies have been carried out. The above extract has been found to promote involucrin production, and the present invention has been completed.

本発明によると、酵母、モモ、アロエ、ノイバラ、トウキンセンカ、アルニカ、ダイダイ、ラベンダー、オトギリソウ、ウンシュウミカン、メリッサ、ヘチマ及びスギナから選ばれる1種又は2種以上の抽出物を有効成分として含有してなるインボルクリン産生促進剤が、優れたインボルクリン産生促進作用を有し、表皮角質細胞の正常化による乾燥肌、荒れ肌、アトピー性皮膚炎、乾癬などの皮膚症状の予防・改善を効果的に行うことができる。   According to the present invention, the composition contains one or more extracts selected from yeast, peach, aloe, Neubara, ginseng, arnica, daidai, lavender, hypericum, Satsuma mandarin, melissa, loofah and cedar as active ingredients. The involucrin production promoter has an excellent involucrin production promoting effect, and effectively prevents and improves skin symptoms such as dry skin, rough skin, atopic dermatitis, psoriasis due to normalization of epidermal keratinocytes. Can do.

本発明のインボルクリン産生促進剤は、酵母、モモ、アロエ、ノイバラ、トウキンセンカ、アルニカ、ダイダイ、ラベンダー、オトギリソウ、ウンシュウミカン、メリッサ、ヘチマ及びスギナから選ばれる1種又は2種以上の抽出物を有効成分として含有してなり、さらに必要に応じてその他の成分を含有してなる。   The involucrin production promoter of the present invention effectively uses one or more extracts selected from yeast, peach, aloe, Neubara, ginseng, arnica, daidai, lavender, hypericum, mandarin orange, melissa, loofah and horsetail. It is contained as a component, and further contains other components as necessary.

前記酵母は、酵母(Saccharomyces属)の自己消化液である 。   The yeast is an autolysate of yeast (genus Saccharomyces).

前記モモは、バラ科(Rosaceae)の植物であり、学名はPrunus persica B.である。 構成部位は特に制限はなく、目的に応じて適宜選定することができ、例えば葉、茎、花、蕾、種子、地上部、全草またはこれらの混合物が挙げられる。これらの中でも特に種子を用いることが好ましい。   The peach is a plant of the Rosaceae family, and its scientific name is Prunus persica B. et al. It is. There is no restriction | limiting in particular in a structure part, According to the objective, it can select suitably, For example, a leaf, a stem, a flower, a bud, a seed, an above-ground part, whole grass, or a mixture thereof is mentioned. Among these, it is particularly preferable to use seeds.

前記アロエは、ユリ科(Liliaceae)の植物であり、学名はAloe ferox;africana Millerである。 構成部位は特に制限はなく、目的に応じて適宜選定することができ、例えば葉、茎、花、蕾、種子、地上部、全草またはこれらの混合物が挙げられる。これらの中でも特に葉を用いることが好ましい。   The aloe is a plant of the liliaceae family and has a scientific name of Aloe ferox; african miller. There is no restriction | limiting in particular in a structure part, According to the objective, it can select suitably, For example, a leaf, a stem, a flower, a bud, a seed, an above-ground part, whole grass, or a mixture thereof is mentioned. Among these, it is particularly preferable to use leaves.

前記ノイバラは、バラ科(Rosaceae)の植物であり、学名はRosa multiflora Thunbergである。 構成部位は特に制限はなく、目的に応じて適宜選定することができ、例えば葉、茎、花、蕾、種子、果実、果皮、果核、地上部、全草またはこれらの混合物が挙げられる。これらの中でも特に果実を用いることが好ましい。   The rose is a plant of the Rosaceae family, and its scientific name is Rosa multiflora Thunberg. There is no restriction | limiting in particular in a structure part, According to the objective, it can select suitably, For example, a leaf, a stem, a flower, a cocoon, a seed, a fruit, a fruit skin, a fruit core, an above-ground part, whole grass, or a mixture thereof is mentioned. Among these, it is particularly preferable to use fruits.

前記トウキンセンカは、キク科(Compositae)の植物であり、学名はCalendula officinalis L.である。 構成部位は特に制限はなく、目的に応じて適宜選定することができ、例えば葉、茎、花、蕾、種子、果実、果皮、果核、地上部、全草またはこれらの混合物が挙げられる。これらの中でも特に花を用いることが好ましい。   The milk moth is a plant of the Compositae family and has a scientific name of Calendula officinalis L. It is. There is no restriction | limiting in particular in a structure part, According to the objective, it can select suitably, For example, a leaf, a stem, a flower, a cocoon, a seed, a fruit, a fruit skin, a fruit core, an above-ground part, whole grass, or a mixture thereof is mentioned. Among these, it is particularly preferable to use flowers.

前記アルニカは、キク科(Compositae)の植物であり、学名はArnica montana L.である。 構成部位は特に制限はなく、目的に応じて適宜選定することができ、例えば葉、茎、花、蕾、種子、果実、果皮、果核、地上部、全草またはこれらの混合物が挙げられる。これらの中でも特に花を用いることが好ましい。   Arnica is a plant of the Compositae family and has the scientific name Arnica montana L. It is. There is no restriction | limiting in particular in a structure part, According to the objective, it can select suitably, For example, a leaf, a stem, a flower, a cocoon, a seed, a fruit, a fruit skin, a fruit core, an above-ground part, whole grass, or a mixture thereof is mentioned. Among these, it is particularly preferable to use flowers.

前記ダイダイは、ミカン科(Rutaceae)の植物であり、学名はCitrus aurantium L.である。 構成部位としては特に制限はなく、目的に応じて適宜選定することができ、例えば葉、茎、花、蕾、果実、果皮、果核、地上部、全草またはこれらの混合物が挙げられる。これらの中でも特に果皮を用いることが好ましい。   The Daidai is a plant of the Rutaceae family, and its scientific name is Citrus aurantium L. It is. There is no restriction | limiting in particular as a structure part, According to the objective, it can select suitably, For example, a leaf, a stem, a flower, a cocoon, a fruit, a fruit skin, a fruit nucleus, an above-ground part, whole grass, or a mixture thereof is mentioned. Among these, it is particularly preferable to use a peel.

前記ラベンダーは、シソ科(Labiatae)の植物であり、学名はLavandula vera D.C.である。 構成部位は特に制限はなく、目的に応じて適宜選定することができ、例えば葉、茎、花、根、果実、果皮、果核またはこれらの混合物が挙げられる。これらの中でも特に花を用いることが好ましい。   The lavender is a plant belonging to the family Labiatae, and the scientific name is Lavandula vera D. et al. C. It is. There is no restriction | limiting in particular in a structure part, According to the objective, it can select suitably, For example, a leaf, a stem, a flower, a root, a fruit, a fruit skin, a fruit nucleus, or a mixture thereof is mentioned. Among these, it is particularly preferable to use flowers.

前記オトギリソウは、オトギリソウ科(Guttiferae)の植物であり、学名はHypericum erectum Thunb.またはHypericum perforatum L.である。 構成部位は特に制限はなく、目的に応じて適宜選定することができ、例えば葉、茎、根、花、地上部、全草またはこれらの混合物が挙げられる。これらの中でも特に地上部または全草を用いることが好ましい。   The hypericum is a plant of the family Glutiferae, and its scientific name is Hypericum electum Thumb. Or Hypericum performancea L. It is. There is no restriction | limiting in particular in a structural part, According to the objective, it can select suitably, For example, a leaf, a stem, a root, a flower, an above-ground part, whole grass, or a mixture thereof is mentioned. Among these, it is particularly preferable to use the above-ground part or whole grass.

前記ウンシュウミカンは、ミカン科(Rutaceae)の植物であり、学名はCitrus unshiu Markovichである。 構成部位は特に制限はなく、目的に応じて適宜選定することができ、例えば葉、茎、枝、花、蕾、果実、果皮、果核、地上部、全草またはこれらの混合物が挙げられる。これらの中でも特に果皮を用いることが好ましい。   The Citrus unshiu is a plant belonging to the family Rutaceae, and its scientific name is Citrus unshiu Markovich. There is no restriction | limiting in particular in a structure part, According to the objective, it can select suitably, For example, a leaf, a stem, a branch, a flower, a cocoon, a fruit, a fruit skin, a fruit core, an above-ground part, whole grass, or a mixture thereof is mentioned. Among these, it is particularly preferable to use a peel.

前記メリッサは、シソ科(Labiatae)の植物であり、学名はMelissa officinalis L.である。 構成部位は特に制限はなく、目的に応じて適宜選定することができ、例えば葉、茎、根、花、果実、果皮、果核、全草またはこれらの混合物が挙げられる。これらの中でも特に葉を用いることが好ましい。   The Melissa is a plant of the Labiatae family and has a scientific name of Melissa officinalis L. It is. There is no restriction | limiting in particular in a structure part, According to the objective, it can select suitably, For example, a leaf, a stem, a root, a flower, a fruit, a fruit peel, a fruit nucleus, whole grass, or a mixture thereof is mentioned. Among these, it is particularly preferable to use leaves.

前記ヘチマは、ウリ科(Cucurbitaceae)の植物であり、学名はLuffa cylindrica M.Roemenである。 構成部位としては特に制限はなく、目的に応じて適宜選定することができるが、例えば葉、茎、花、蕾、果実、果皮、果核、地上部またはこれらの混合物が挙げられ、これらの中でも前記地上部が好ましい。   The loofah is a plant of the Cucurbitaceae family, and its scientific name is Luffa cylindrica M. et al. Roemen. There are no particular restrictions on the constituent parts, and it can be appropriately selected according to the purpose, and examples thereof include leaves, stems, flowers, persimmons, fruits, pericarps, fruit nuclei, above-ground parts, or a mixture thereof. The aerial part is preferred.

前記スギナは、トクサ科(Equisetaceae)の植物であり、学名はEquisetum arvense L.である。 構成部位は特に制限はなく、目的に応じて適宜選定することができるが、特に全草を用いることが好ましい。   The horsetail is a plant belonging to the family Equisetaceae, and its scientific name is Equisetum arvense L. et al. It is. The constituent parts are not particularly limited and can be appropriately selected according to the purpose, but it is particularly preferable to use whole plants.

なお、前記酵母、モモ、アロエ、ノイバラ、トウキンセンカ、アルニカ、ダイダイ、ラベンダー、オトギリソウ、ウンシュウミカン、メリッサ、ヘチマ及びスギナから選ばれる1種又は2種以上の抽出物を有効成分として含有するインボルクリン産生促進作用物質の詳細については不明であるが、これらの有効成分は植物の抽出に一般に用いられている方法により抽出したものを使用してもよいし、市販品を使用してもよい。前記抽出物には、抽出処理によって抽出原料から得られる抽出液、該抽出液の希釈液もしくは濃縮液、該抽出液を乾燥して得られる乾燥物、又はこれらの粗精製物もしくは精製物のいずれもが含まれる。   Involucrin production containing as an active ingredient one or more extracts selected from the yeast, peach, aloe, Neubara, ginseng, Arnica, Daidai, Lavender, Hypericum, Unshimikan, Melissa, Loofah and Sugiina Although details of the accelerating agent are unknown, those active ingredients may be extracted by a method generally used for plant extraction, or commercially available products may be used. The extract includes any one of an extract obtained from an extraction raw material by an extraction process, a diluted or concentrated solution of the extract, a dried product obtained by drying the extract, or a roughly purified product or a purified product thereof. Is also included.

前記抽出原料は、採取後ただちに乾燥し粉砕したものが適当である。乾燥は天日で行ってもよいし、通常使用される乾燥機を用いて行ってもよい。また、ヘキサン、ベンゼン等の非極性溶媒によって脱脂等の前処理を施してから抽出原料として使用してもよい。   The extraction raw material is suitably dried and pulverized immediately after collection. Drying may be performed in the sun or using a commonly used dryer. Moreover, after performing pre-processing, such as degreasing, with nonpolar solvents, such as hexane and benzene, you may use as an extraction raw material.

前記抽出に用いる溶媒としては、水若しくは親水性有機溶媒又はこれらの混合液を室温又は溶媒の沸点以下の温度で用いることが好ましい。各植物に含まれるインボルクリン産生促進作用を示す成分は、極性溶媒を抽出溶媒とする抽出処理によって容易に抽出することができる。   As the solvent used for the extraction, it is preferable to use water, a hydrophilic organic solvent, or a mixture thereof at room temperature or a temperature not higher than the boiling point of the solvent. A component showing the involucrin production promoting action contained in each plant can be easily extracted by an extraction treatment using a polar solvent as an extraction solvent.

前記抽出溶媒として使用し得る水としては、例えば、純水、水道水、井戸水、鉱泉水、鉱水、温泉水、湧水、淡水等の他、これらに各種処理を施したものが含まれる。水に施す処理としては、例えば、精製、加熱、殺菌、ろ過、イオン交換、浸透圧の調整、緩衝化等が含まれる。従って、本発明において抽出溶媒として使用し得る水には、精製水、熱水、イオン交換水、生理食塩水、リン酸緩衝液、リン酸緩衝生理食塩水等も含まれる。   Examples of water that can be used as the extraction solvent include pure water, tap water, well water, mineral spring water, mineral water, hot spring water, spring water, fresh water, and the like, as well as water that has been subjected to various treatments. Examples of the treatment applied to water include purification, heating, sterilization, filtration, ion exchange, adjustment of osmotic pressure, buffering, and the like. Therefore, the water that can be used as the extraction solvent in the present invention includes purified water, hot water, ion-exchanged water, physiological saline, phosphate buffer, phosphate buffered saline, and the like.

前記親水性有機溶媒としては、例えば、メタノール、エタノール、プロピルアルコール、イソプロピルアルコール等の炭素数1〜5の低級アルコール;アセトン、メチルエチルケトン等の低級脂肪族ケトン;1,3−ブチレングリコール、プロピレングリコール、グリセリン等の炭素数2〜5の多価アルコールなどが挙げられ、該親水性有機溶媒と水との混合溶媒などを用いることができる。   Examples of the hydrophilic organic solvent include lower alcohols having 1 to 5 carbon atoms such as methanol, ethanol, propyl alcohol, and isopropyl alcohol; lower aliphatic ketones such as acetone and methyl ethyl ketone; 1,3-butylene glycol, propylene glycol, Examples thereof include polyhydric alcohols having 2 to 5 carbon atoms such as glycerin, and a mixed solvent of the hydrophilic organic solvent and water can be used.

なお、前記水と親水性有機溶媒との抽出溶媒を使用する場合には、低級アルコールの場合は水10質量部に対して1〜90質量部、低級脂肪族ケトンの場合は水10質量部に対して1〜40質量部添加することが好ましい。多価アルコールの場合は水10質量部に対して1〜90質量部添加することが好ましい。   In addition, when using the extraction solvent of the said water and a hydrophilic organic solvent, in the case of a lower alcohol, it is 1-90 mass parts with respect to 10 mass parts of water, and in the case of a lower aliphatic ketone, it is 10 mass parts of water. It is preferable to add 1-40 mass parts with respect to it. In the case of a polyhydric alcohol, it is preferable to add 1 to 90 parts by mass with respect to 10 parts by mass of water.

本発明において、前記各抽出原料からインボルクリン産生促進物質を抽出するにあたって特殊な抽出方法を採用する必要はなく、室温又は還流加熱下で、任意の装置を用いて抽出することができる。   In the present invention, it is not necessary to employ a special extraction method for extracting the involucrin production promoting substance from each of the extraction raw materials, and the extraction can be performed using an arbitrary apparatus at room temperature or under reflux heating.

具体的には、抽出溶媒を満たした処理槽に各抽出原料を投入し、更に必要に応じて時々攪拌しながら、30分〜4時間静置して可溶性成分を溶出した後、ろ過して固形物を除去し、得られた抽出液から抽出溶媒を留去し、乾燥することにより抽出物が得られる。抽出溶媒量は通常、抽出原料の5〜15倍量(質量比)である。抽出条件は、抽出溶媒として水を用いた場合には、通常50〜95℃で1〜4時間程度である。また、抽出溶媒として水とエタノールとの混合溶媒を用いた場合には、通常40〜80℃で30分〜4時間程度である。なお、溶媒で抽出することにより得られる抽出液は、抽出溶媒が安全性の高いものであればそのまま配合して本発明のインボルクリン産生促進剤及び/又は表皮角化正常化剤の有効成分として使用することができるが、濃縮液又はその乾燥物としたものの方が利用しやすい。   Specifically, each extraction raw material is put into a treatment tank filled with an extraction solvent, and further, while stirring occasionally as necessary, the mixture is allowed to stand for 30 minutes to 4 hours to elute soluble components, and then filtered and solidified. An extract is obtained by removing a thing, distilling an extraction solvent off from the obtained extract, and drying. The amount of the extraction solvent is usually 5 to 15 times (mass ratio) of the extraction raw material. The extraction condition is usually about 1 to 4 hours at 50 to 95 ° C. when water is used as the extraction solvent. Moreover, when using the mixed solvent of water and ethanol as an extraction solvent, it is about 30 minutes-4 hours at 40-80 degreeC normally. In addition, the extract obtained by extracting with a solvent is used as an active ingredient of the involucrin production promoter and / or epidermal keratinization normalizing agent of the present invention as it is if the extraction solvent is highly safe. However, it is easier to use a concentrated solution or a dried product thereof.

得られた抽出液は、該抽出液の希釈液若しくは濃縮液、該抽出液の乾燥物、又はこれらの粗精製物若しくは精製物を得るために、常法に従って希釈、濃縮、乾燥、精製等の処理を施してもよい。   The obtained extract is diluted, concentrated, dried, purified, etc. according to a conventional method in order to obtain a diluted or concentrated solution of the extract, a dried product of the extract, or a crude purified product or a purified product thereof. Processing may be performed.

なお、得られた抽出液はそのままでもインボルクリン産生促進剤及び/又は表皮角化正常化剤として使用することができるが、濃縮液又はその乾燥物としたものの方が利用しやすい。乾燥物を得るにあたっては、吸湿性を改善するためにデキストリン、シクロデキストリン等のキャリアーを添加してもよい。   In addition, although the obtained extract can be used as it is as an involucrin production promoter and / or a skin keratinization normalizing agent, a concentrated solution or a dried product thereof is easier to use. In obtaining a dried product, a carrier such as dextrin or cyclodextrin may be added to improve hygroscopicity.

また、各抽出原料は特有の匂いと味を有しているため、その生理活性の低下を招かない範囲で脱色、脱臭等を目的とする精製を行うことも可能であるが、化粧料に添加する場合には大量に使用するものではないから、未精製のままでも実用上支障はない。精製は、具体的には活性炭処理、吸着樹脂処理、イオン交換樹脂処理等によって行うことができる。   In addition, since each extraction raw material has a unique odor and taste, it is possible to carry out purification for the purpose of decolorization, deodorization, etc. within a range that does not cause a decrease in its physiological activity, but it is added to cosmetics. In this case, since it is not used in large quantities, there is no practical problem even if it is not purified. Specifically, purification can be performed by activated carbon treatment, adsorption resin treatment, ion exchange resin treatment, or the like.

本発明のインボルクリン産生促進剤及び/又は表皮角化正常化剤は、製剤化により粉末状、顆粒状、錠剤状等、任意の剤形とすることができる。   The involucrin production promoter and / or epidermal keratinization normalizing agent of the present invention can be made into any dosage form such as powder, granule, tablet, etc. by formulation.

以下、本発明の実施例を説明するが、本発明は、これらの実施例に何ら限定されるものではない。なお、本実施例で使用する、前記酵母抽出液、トウニン抽出液、アロエ抽出液、エイジツ抽出液−R、トウキンセンカ抽出液、アルニカ抽出液、トウヒ抽出液、ラベンダー抽出液、オトギリソウ抽出液−J、チンピ抽出液、メリッサ抽出液−J、ヘチマ抽出液−JC及びスギナ抽出液(全て丸善製薬社製)の各凍結乾燥品を試料として用いた。   Examples of the present invention will be described below, but the present invention is not limited to these examples. In addition, the yeast extract, tonin extract, aloe extract, Agetsu extract-R, eucalyptus extract, arnica extract, spruce extract, lavender extract, hypericum extract-J used in this example. Each lyophilized product of Chimpi extract, Melissa extract-J, Loofah extract-JC and Sugina extract (all manufactured by Maruzen Pharmaceutical Co., Ltd.) was used as a sample.

[試験例1]インボルクリン産生促進作用試験
上記の各抽出物について、下記の方法によりインボルクリン産生促進作用の試験をした。
正常ヒト皮膚表皮角化細胞(NHEK)を80cmのフラスコで正常ヒト表皮角化細胞培地(KGM)にて37℃、5%CO下で培養し、トリプシン処理により細胞を回収した。回収した細胞を1.5×10個/mLの細胞密度となるようにKGMで希釈した後、48ウェルプレートに1ウェルあたり200μLずつ播種し、5%CO下、37℃で3日間培養した。
[Test Example 1] Involucrin production promoting action test
Each of the above extracts was tested for involucrin production promoting action by the following method.
Normal human skin epidermal keratinocytes (NHEK) were cultured in normal human epidermal keratinocyte medium (KGM) at 37 ° C. and 5% CO 2 in an 80 cm 2 flask, and the cells were collected by trypsin treatment. The collected cells are diluted with KGM to a cell density of 1.5 × 10 4 cells / mL, then seeded at 200 μL per well in a 48-well plate, and cultured at 37 ° C. under 5% CO 2 for 3 days. did.

培養終了後、培地を抜き、KGMで溶解した試料溶液を各ウェルに200μLずつ添加し、37℃、5%CO下で48時間培養した。培養終了後、 培地を抜き、細胞をプレートに固定させ細胞表面に発現したインボルクリンの量をモノクローナル抗ヒトインボルクリン抗体を用いたELISA法により測定した。得られた測定結果から、下記式によりインボルクリン産生促進率(%)を算出した。
インボルクリン産生促進率(%)=A/B × 100
式中、Aは「試料添加時の波長405nmにおける吸光度」を表し、Bは「試料無添加時の波長405nmにおける吸光度」を表す。
After completion of the culture, the medium was removed, 200 μL of a sample solution dissolved in KGM was added to each well, and the cells were cultured at 37 ° C. under 5% CO 2 for 48 hours. After completion of the culture, the medium was removed, the cells were fixed on a plate, and the amount of involucrin expressed on the cell surface was measured by ELISA using a monoclonal anti-human involucrin antibody. From the obtained measurement results, the involucrin production promotion rate (%) was calculated by the following formula.
Involucrin production promotion rate (%) = A / B × 100
In the formula, A represents “absorbance at a wavelength of 405 nm when a sample is added”, and B represents “absorbance at a wavelength of 405 nm when no sample is added”.

上記試験の結果を表1〜13に示す。なお、上記計算式において、試料無添加のインボルクリン産生促進率は100%となる。   The result of the said test is shown to Tables 1-13. In the above calculation formula, the involucrin production promotion rate without addition of the sample is 100%.

[表1]
酵母抽出物の添加濃度 インボルクリン産生促進率
100.0μ g/mL 119.6%
25.0μ g/mL 108.6%
[Table 1]
Yeast extract added concentration Involucrin production promotion rate
100.0 μg / mL 119.6%
25.0 μg / mL 108.6%

[表2]
モモの種子抽出物の添加濃度 インボルクリン産生促進率
100.0μ g/mL 108.6%
25.0μ g/mL 106.2%
[Table 2]
Increasing rate of involucrin production by adding peach seed extract
100.0 μg / mL 108.6%
25.0 μg / mL 106.2%

[表3]
アロエの葉抽出物の添加濃度 インボルクリン産生促進率
100.0μ g/mL 104.2%
25.0μ g/mL 106.3%
[Table 3]
Increasing rate of involculin production by adding aloe leaf extract
100.0 μg / mL 104.2%
25.0 μg / mL 106.3%

[表4]
ノイバラの果実抽出物の添加濃度 インボルクリン産生促進率
100.0μ g/mL 154.5%
25.0μ g/mL 135.9%
[Table 4]
Increased rate of involucrin production in fruit extract of rosehip
100.0 μg / mL 154.5%
25.0 μg / mL 135.9%

[表5]
トウキンセンカの花抽出物の添加濃度 インボルクリン産生促進率
100.0μ g/mL 135.6%
25.0μ g/mL 120.9%
[Table 5]
Increasing rate of involucrin production with added concentration of flower extract
100.0 μg / mL 135.6%
25.0 μg / mL 120.9%

[表6]
アルニカの花抽出物の添加濃度 インボルクリン産生促進率
25.0μ g/mL 136.2%
[Table 6]
Increasing rate of involcrine production with Arnica flower extract
25.0 μg / mL 136.2%

[表7]
ダイダイの果皮抽出物の添加濃度 インボルクリン産生促進率
100.0μ g/mL 134.7%
25.0μ g/mL 144.1%
[Table 7]
Increased rate of involucrin production in Daidai peel extract
100.0 μg / mL 134.7%
25.0 μg / mL 144.1%

[表8]
ラベンダーの花抽出物の添加濃度 インボルクリン産生促進率
100.0μ g/mL 127.4%
25.0μ g/mL 100.9%
[Table 8]
Increasing rate of involucrin production by adding lavender flower extract
100.0 μg / mL 127.4%
25.0 μg / mL 100.9%

[表9]
オトギリソウの全草抽出物の添加濃度 インボルクリン産生促進率
50.0μ g/mL 123.7%
12.5μ g/mL 109.7%
[Table 9]
Increasing rate of involcrine production by the concentration of hypericum whole plant extract
50.0 μg / mL 123.7%
12.5 μg / mL 109.7%

[表10]
ウンシュウミカンの果皮抽出物の添加濃度 インボルクリン産生促進率
50.0μ g/mL 132.7%
12.5μ g/mL 141.2%
[Table 10]
Increasing rate of involucrin production in the concentration of Citrus unshiu peel extract
50.0 μg / mL 132.7%
12.5 μg / mL 141.2%

[表11]
メリッサの葉抽出物の添加濃度 インボルクリン産生促進率
50.0μ g/mL 147.5%
12.5μ g/mL 117.6%
[Table 11]
Melissa leaf extract added concentration Involcrine production promotion rate
50.0 μg / mL 147.5%
12.5 μg / mL 117.6%

[表12]
ヘチマの地上部抽出物の添加濃度 インボルクリン産生促進率
12.5μ g/mL 112.3%
[Table 12]
Increased rate of involucrin production in the ground extract of loofah
12.5 μg / mL 112.3%

[表13]
スギナの全草抽出物の添加濃度 インボルクリン産生促進率
50.0μ g/mL 111.5%
12.5μ g/mL 115.8%
[Table 13]
Increasing rate of involucrin production by the concentration of whole plant extracts of horsetail
50.0 μg / mL 111.5%
12.5 μg / mL 115.8%

表1〜13に示すように、酵母、モモ、アロエ、ノイバラ、トウキンセンカ、アルニカ、ダイダイ、ラベンダー、オトギリソウ、ウンシュウミカン、メリッサ、ヘチマ及び/又はスギナから選ばれる抽出物は、いずれも高いインボルクリン産生促進率を示した。この結果から、これらの抽出物は、優れたインボルクリン産生促進作用を有することが確認された。   As shown in Tables 1 to 13, the extract selected from yeast, peach, aloe, Neubara, ginseng, arnica, daidai, lavender, hypericum, Satsuma mandarin, Melissa, loofah and / or horsetail is high in invorcrine production. The promotion rate was shown. From these results, it was confirmed that these extracts have an excellent involucrin production promoting action.

本発明のインボルクリン産生促進剤及び表皮角化正常化剤は、表皮におけるインボルクリンの産生促進作用によって表皮角質細胞を正常化させることにより、乾燥肌、荒れ肌、アトピー性皮膚炎、乾癬などの皮膚症状の予防・改善に大きく貢献できる。   The involucrin production promoting agent and epidermal keratinization normalizing agent of the present invention normalizes epidermal keratinocytes by involucrin production promoting action in the epidermis, thereby reducing skin symptoms such as dry skin, rough skin, atopic dermatitis, and psoriasis. Can greatly contribute to prevention and improvement.

Claims (2)

酵母、モモ、アロエ、ノイバラ、トウキンセンカ、アルニカ、ダイダイ、ラベンダー、オトギリソウ、ウンシュウミカン、メリッサ、ヘチマ及びスギナから選ばれる1種又は2種以上の抽出物を有効成分として含有することを特徴とするインボルクリン産生促進剤。 It contains one or more extracts selected from yeast, peach, aloe, Neubara, ginseng, arnica, daidai, lavender, hypericum, unshimikan, melissa, loofah and horsetail as an active ingredient Involucrin production promoter. 請求項1記載の抽出物を有効成分として含有することを特徴とする表皮角化正常化剤。 A skin keratinizing normalizing agent comprising the extract according to claim 1 as an active ingredient.
JP2006176086A 2006-06-27 2006-06-27 Involucrin production promoter and epidermal keratinization-normalizing agent Pending JP2008007412A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2006176086A JP2008007412A (en) 2006-06-27 2006-06-27 Involucrin production promoter and epidermal keratinization-normalizing agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006176086A JP2008007412A (en) 2006-06-27 2006-06-27 Involucrin production promoter and epidermal keratinization-normalizing agent

Publications (1)

Publication Number Publication Date
JP2008007412A true JP2008007412A (en) 2008-01-17

Family

ID=39065934

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006176086A Pending JP2008007412A (en) 2006-06-27 2006-06-27 Involucrin production promoter and epidermal keratinization-normalizing agent

Country Status (1)

Country Link
JP (1) JP2008007412A (en)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008007411A (en) * 2006-06-27 2008-01-17 Maruzen Pharmaceut Co Ltd Transglutaminase production promoter and epidermal keratinization-normalizing agent
JP2009084195A (en) * 2007-09-28 2009-04-23 Naris Cosmetics Co Ltd Involucrin production promoter
JP2011088845A (en) * 2009-10-21 2011-05-06 Kao Corp Involucrin expression inhibitor
JP2011088854A (en) * 2009-10-22 2011-05-06 Kao Corp Involucrin expression inhibitor
JP2012171949A (en) * 2011-02-24 2012-09-10 Nagase & Co Ltd Expression enhancer of melatonin receptor and method for producing the same
CN102813691A (en) * 2011-06-09 2012-12-12 株式会社芳珂 MIF secretion inhibitor
JP2014088368A (en) * 2012-10-02 2014-05-15 Mikimoto Pharmaceut Co Ltd Involucrin production promoter and skin barrier function reinforcing agent
JP2014136692A (en) * 2013-01-17 2014-07-28 Nagase & Co Ltd Epithelium barrier function enhancer
JP2014521698A (en) * 2011-08-05 2014-08-28 ステムテック インターナショナル, インコーポレイテッド Skin care composition containing a combination of natural ingredients
KR20160054683A (en) * 2014-11-06 2016-05-17 주식회사 엘지생활건강 Composition for promoting synthesis of hyaluronic acid comprising Citrii Unshiu Immaturi Pericarpium extracts and the use thereof
JP2017160186A (en) * 2016-03-07 2017-09-14 御木本製薬株式会社 Kallikrein associated peptidase production-promoting agent, lekti production-promoting agent, slpi production-promoting agent, cornification normalizing agent, and corneodesmosome degradation normalizing agent
JP2018002703A (en) * 2016-06-23 2018-01-11 御木本製薬株式会社 Psoriasin production promoter
JP2019081712A (en) * 2017-10-27 2019-05-30 丸善製薬株式会社 Nerve growth factor expression inhibitor and semaphorin 3A expression promoter
JP2020130056A (en) * 2019-02-20 2020-08-31 株式会社ダイセル Oral composition for improving skin barrier function
JP2021038168A (en) * 2019-09-03 2021-03-11 ちふれホールディングス株式会社 Composition for suppressing deterioration of skin barrier function
JP2021169532A (en) * 2016-03-07 2021-10-28 御木本製薬株式会社 Transglutaminase production promoter
JP2021183571A (en) * 2020-05-22 2021-12-02 ちふれホールディングス株式会社 Cosmetic composition

Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09241147A (en) * 1996-03-06 1997-09-16 Noevir Co Ltd Skin external agent
JPH09315930A (en) * 1996-05-28 1997-12-09 Kanebo Ltd Cosmetic material for skin
JPH10182402A (en) * 1996-12-25 1998-07-07 Nagase & Co Ltd Agent for promoting synthesis of hyaluronic acid
JPH10279491A (en) * 1997-04-01 1998-10-20 Kao Corp Interleukin 4 production inhibitor
JPH10279427A (en) * 1997-03-31 1998-10-20 Sunstar Inc Moisture-retaining cosmetic material composition
JPH1129460A (en) * 1997-07-04 1999-02-02 Pola Chem Ind Inc Cosmetic for sensitive skin
JPH11279069A (en) * 1998-03-27 1999-10-12 Ichimaru Pharcos Co Ltd Active oxygen eliminating agent
JP2000096050A (en) * 1998-09-25 2000-04-04 Shiseido Co Ltd Promoter for production of hyaluronic acid
JP2000169383A (en) * 1998-12-07 2000-06-20 Ichimaru Pharcos Co Ltd Antiallergic agent
JP2000169359A (en) * 1998-09-30 2000-06-20 Kao Corp Ceramide production promoter
JP2001163757A (en) * 1999-12-08 2001-06-19 Noevir Co Ltd Preparation for external use for skin
CN1413720A (en) * 2002-09-29 2003-04-30 程光智 Chinese drugs for treating psoriasis and its preparation method
JP2003171310A (en) * 2002-05-02 2003-06-20 Noevir Co Ltd Skin barrier function-reinforcing agent
JP2003261435A (en) * 2002-03-11 2003-09-16 Ichimaru Pharcos Co Ltd Energy modifying agent
JP2004323468A (en) * 2003-04-28 2004-11-18 Noevir Co Ltd Skin care preparation for external use
JP2005213187A (en) * 2004-01-29 2005-08-11 Kose Corp Involucrin production promoter
JP2006016337A (en) * 2004-07-01 2006-01-19 Maruzen Pharmaceut Co Ltd Filaggrin production-accelerating agent and skin cosmetic
JP2006124350A (en) * 2004-11-01 2006-05-18 Nippon Menaade Keshohin Kk Nmf production promoter
JP2007008911A (en) * 2005-07-04 2007-01-18 Kanebo Cosmetics Inc Cosmetic
JP2007176835A (en) * 2005-12-27 2007-07-12 Pola Chem Ind Inc External preparation for skin, for improving skin barrier function and its production method

Patent Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09241147A (en) * 1996-03-06 1997-09-16 Noevir Co Ltd Skin external agent
JPH09315930A (en) * 1996-05-28 1997-12-09 Kanebo Ltd Cosmetic material for skin
JPH10182402A (en) * 1996-12-25 1998-07-07 Nagase & Co Ltd Agent for promoting synthesis of hyaluronic acid
JPH10279427A (en) * 1997-03-31 1998-10-20 Sunstar Inc Moisture-retaining cosmetic material composition
JPH10279491A (en) * 1997-04-01 1998-10-20 Kao Corp Interleukin 4 production inhibitor
JPH1129460A (en) * 1997-07-04 1999-02-02 Pola Chem Ind Inc Cosmetic for sensitive skin
JPH11279069A (en) * 1998-03-27 1999-10-12 Ichimaru Pharcos Co Ltd Active oxygen eliminating agent
JP2000096050A (en) * 1998-09-25 2000-04-04 Shiseido Co Ltd Promoter for production of hyaluronic acid
JP2000169359A (en) * 1998-09-30 2000-06-20 Kao Corp Ceramide production promoter
JP2000169383A (en) * 1998-12-07 2000-06-20 Ichimaru Pharcos Co Ltd Antiallergic agent
JP2001163757A (en) * 1999-12-08 2001-06-19 Noevir Co Ltd Preparation for external use for skin
JP2003261435A (en) * 2002-03-11 2003-09-16 Ichimaru Pharcos Co Ltd Energy modifying agent
JP2003171310A (en) * 2002-05-02 2003-06-20 Noevir Co Ltd Skin barrier function-reinforcing agent
CN1413720A (en) * 2002-09-29 2003-04-30 程光智 Chinese drugs for treating psoriasis and its preparation method
JP2004323468A (en) * 2003-04-28 2004-11-18 Noevir Co Ltd Skin care preparation for external use
JP2005213187A (en) * 2004-01-29 2005-08-11 Kose Corp Involucrin production promoter
JP2006016337A (en) * 2004-07-01 2006-01-19 Maruzen Pharmaceut Co Ltd Filaggrin production-accelerating agent and skin cosmetic
JP2006124350A (en) * 2004-11-01 2006-05-18 Nippon Menaade Keshohin Kk Nmf production promoter
JP2007008911A (en) * 2005-07-04 2007-01-18 Kanebo Cosmetics Inc Cosmetic
JP2007176835A (en) * 2005-12-27 2007-07-12 Pola Chem Ind Inc External preparation for skin, for improving skin barrier function and its production method

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008007411A (en) * 2006-06-27 2008-01-17 Maruzen Pharmaceut Co Ltd Transglutaminase production promoter and epidermal keratinization-normalizing agent
JP2009084195A (en) * 2007-09-28 2009-04-23 Naris Cosmetics Co Ltd Involucrin production promoter
JP2011088845A (en) * 2009-10-21 2011-05-06 Kao Corp Involucrin expression inhibitor
JP2011088854A (en) * 2009-10-22 2011-05-06 Kao Corp Involucrin expression inhibitor
JP2012171949A (en) * 2011-02-24 2012-09-10 Nagase & Co Ltd Expression enhancer of melatonin receptor and method for producing the same
TWI504400B (en) * 2011-06-09 2015-10-21 Fancl Corp Mif secretion inhibitor
CN102813691A (en) * 2011-06-09 2012-12-12 株式会社芳珂 MIF secretion inhibitor
JP2012254955A (en) * 2011-06-09 2012-12-27 Fancl Corp Mif secretion inhibitor
JP2014521698A (en) * 2011-08-05 2014-08-28 ステムテック インターナショナル, インコーポレイテッド Skin care composition containing a combination of natural ingredients
JP2014088368A (en) * 2012-10-02 2014-05-15 Mikimoto Pharmaceut Co Ltd Involucrin production promoter and skin barrier function reinforcing agent
JP2014136692A (en) * 2013-01-17 2014-07-28 Nagase & Co Ltd Epithelium barrier function enhancer
KR20160054683A (en) * 2014-11-06 2016-05-17 주식회사 엘지생활건강 Composition for promoting synthesis of hyaluronic acid comprising Citrii Unshiu Immaturi Pericarpium extracts and the use thereof
KR102393352B1 (en) * 2014-11-06 2022-05-03 주식회사 엘지생활건강 Composition for promoting synthesis of hyaluronic acid comprising Citrii Unshiu Immaturi Pericarpium extracts and the use thereof
JP2021169532A (en) * 2016-03-07 2021-10-28 御木本製薬株式会社 Transglutaminase production promoter
JP2017160186A (en) * 2016-03-07 2017-09-14 御木本製薬株式会社 Kallikrein associated peptidase production-promoting agent, lekti production-promoting agent, slpi production-promoting agent, cornification normalizing agent, and corneodesmosome degradation normalizing agent
JP7021762B2 (en) 2016-03-07 2022-02-17 御木本製薬株式会社 Kallikrein-related peptidase production promoter, LEKTI production promoter, SLPI production promoter, keratinization normalizer, corneodesmosome degradation normalizer
JP2018002703A (en) * 2016-06-23 2018-01-11 御木本製薬株式会社 Psoriasin production promoter
JP2019081712A (en) * 2017-10-27 2019-05-30 丸善製薬株式会社 Nerve growth factor expression inhibitor and semaphorin 3A expression promoter
JP2020130056A (en) * 2019-02-20 2020-08-31 株式会社ダイセル Oral composition for improving skin barrier function
JP2021038168A (en) * 2019-09-03 2021-03-11 ちふれホールディングス株式会社 Composition for suppressing deterioration of skin barrier function
JP7382181B2 (en) 2019-09-03 2023-11-16 ちふれホールディングス株式会社 Composition for suppressing skin barrier function decline
JP2021183571A (en) * 2020-05-22 2021-12-02 ちふれホールディングス株式会社 Cosmetic composition

Similar Documents

Publication Publication Date Title
JP2008007412A (en) Involucrin production promoter and epidermal keratinization-normalizing agent
JP2008007411A (en) Transglutaminase production promoter and epidermal keratinization-normalizing agent
JP2009084216A (en) Atp production promoter and epidermal cell activator
JP2009256244A (en) Claudin production promoter, occludin production promoter and skin barrier function-improving agent
JP4768238B2 (en) Profilagrin mRNA expression promoter
JP5860579B2 (en) Filaggrin production promoter, involucrin production promoter, and transglutaminase-1 production promoter
JP2009256271A (en) AQUAPORIN 3 mRNA EXPRESSION PROMOTOR AND SKIN MOISTURE RETENTION FUNCTION-IMPROVING AGENT
JP2009298723A (en) Type iv collagen production promoter
JP2009040757A (en) Agent promoting laminin 5 production, agent normalizing dermal basement membrane, and agent promoting recovery of skin lesion
JP2009191039A (en) EXPRESSION PROMOTOR FOR HYALURONIC ACID SYNTHETASE 3mRNA, EXPRESSION PROMOTOR FOR AQUAPORIN 3mRNA, EXPRESSION PROMOTOR FOR SERINE PALMITOYLTRANSFERASE mRNA, AND PRODUCTION PROMOTOR FOR LAMININ 5
JP2008255051A (en) Ceramide synthesis promoter, skin barrier function-ameliorating agent, and agent for preventing and treating disease caused by ceramide synthesis trouble
JP2006316028A (en) Antiaging agent and epidermal keratinizing cell proliferation accelerator
JP2014221739A (en) Type vii collagen expression promoter
JP5067916B2 (en) Skin cosmetics and hair cosmetics
JP2010065007A (en) Claudin-1 production promoter and skin barrier function improving agent
JP5668001B2 (en) Skin cosmetics and hair cosmetics
JP2009067701A (en) Growth promoter of keratinized cell of epidermis and transglutaminase-1 production promoter
JP2009114146A (en) Transglutaminase-1 production promoter and involucrin production promoter
JP2022050090A (en) Collagen type i production promoter
JP2011068570A (en) Laminin-5 production promoter, dermal basement membrane normalizing agent and skin damage recovery promoter
JP6175216B2 (en) Preventive and therapeutic agents for arthritis
JP2008285423A (en) Pro-filaggrin production promoter, filaggrin production promoter and pore conspicuity inhibitor
JP5110676B2 (en) Singlet oxygen scavenger, hyaluronidase inhibitor and hexosaminidase release inhibitor
JP2008285424A (en) Profilaggrin production promoter, filaggrin production promoter and cyclooxygenase 2 activity inhibitor
JP2021031417A (en) Transglutaminase-1 production promoter

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090519

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20090519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120307

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120507

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120808

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121009

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130306